After enrollment, patients will enter the 1-week single-blind placebo period during which all patients will receive a single 30-minute IV infusion of placebo. Thereafter, patients will enter the double-blind treatment period and will receive 30-minute IV infusions of Study Drug (ATYR1940 or placebo) according to their random treatment assignment.